Spots Global Cancer Trial Database for adult solid neoplasm
Every month we try and update this database with for adult solid neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT01375829 | Adult Solid Neo... | Ixabepilone Pharmacological... Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors | NCT01154426 | Adult Solid Neo... BRCA1 Mutation ... BRCA2 Mutation ... | Diagnostic Labo... Gemcitabine Hyd... Pharmacological... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | NCT00334789 | Adult Solid Neo... | Belinostat Isotretinoin Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors | NCT01971489 | Adult Solid Neo... Recurrent Non-S... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-Sm... | Buparlisib Cisplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological... Questionnaire A... | 18 Years - | Roswell Park Cancer Institute | |
| A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain | NCT01269918 | Adult Intracran... Adult Solid Tum... | Remifentanil Dexmedetomidine | 18 Years - 80 Years | The Cleveland Clinic | |
| Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery | NCT00410553 | Adult Solid Neo... Recurrent Ovari... Recurrent Uteri... Stage III Ovari... Stage III Uteri... Stage IV Ovaria... Stage IV Uterin... | Eribulin Mesyla... Gemcitabine Hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Improving Communication in Older Cancer Patients and Their Caregivers | NCT02107443 | Adult Solid Neo... Lymphoma | Geriatric Asses... Geriatric Asses... Geriatric Asses... | 70 Years - | University of Rochester | |
| Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | NCT00070252 | Adult Solid Neo... Inflammatory Br... Male Breast Car... Stage IIIA Brea... Stage IIIB Brea... | Capecitabine Docetaxel Laboratory Biom... Pharmacological... Tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors | NCT00045201 | Adult Solid Neo... | Erlotinib Hydro... Irinotecan Hydr... | 18 Years - | National Cancer Institute (NCI) | |
| Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors | NCT01654965 | Adult Solid Neo... | Laboratory Biom... Pegfilgrastim Pharmacological... Tivantinib Topotecan Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | NCT01093092 | Adult Solid Neo... | Calcitriol Cisplatin Gemcitabine Hyd... Pharmacological... | 18 Years - | Roswell Park Cancer Institute | |
| High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors | NCT01281176 | Adult Solid Neo... | Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Vorinostat | 19 Years - | National Cancer Institute (NCI) | |
| Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | NCT01264432 | Adult Solid Neo... Peritoneal Carc... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Laboratory Biom... Quality-of-Life... Radiation Thera... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | NCT00334789 | Adult Solid Neo... | Belinostat Isotretinoin Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Pocket Phantom Tool in Improving Accuracy of Quantitative PET/CT Imaging of Patients With Solid Tumors | NCT02822365 | Adult Solid Neo... | Computed Tomogr... Imaging Phantom... Positron Emissi... | 21 Years - | University of Washington | |
| Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors | NCT00045201 | Adult Solid Neo... | Erlotinib Hydro... Irinotecan Hydr... | 18 Years - | National Cancer Institute (NCI) | |
| MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer | NCT01263145 | Adult Solid Neo... Recurrent Breas... Stage IV Breast... | Akt Inhibitor M... Laboratory Biom... Paclitaxel Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies | NCT01061749 | Adult Solid Neo... | Cixutumumab Laboratory Biom... Pharmacological... Selumetinib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer | NCT00535119 | Adult Solid Neo... BRCA1 Mutation ... BRCA2 Mutation ... Hereditary Brea... | Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | NCT01131234 | Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Adult Solid Neo... Male Breast Car... Recurrent Adult... Recurrent Breas... Recurrent Colon... Recurrent Melan... Recurrent Non-S... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Renal... Stage III Pancr... Stage III Renal... Stage IIIA Colo... Stage IIIA Non-... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Rect... Stage IIIA Skin... Stage IIIB Brea... Stage IIIB Colo... Stage IIIB Non-... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Rect... Stage IIIB Skin... Stage IIIC Brea... Stage IIIC Colo... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Rect... Stage IIIC Skin... Stage IV Breast... Stage IV Non-Sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Renal ... Stage IV Skin M... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... | Gamma-Secretase... Cediranib Malea... Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery | NCT01625156 | Adult Solid Neo... | Laboratory Biom... Pharmacological... Temsirolimus Tivantinib | 18 Years - | National Cancer Institute (NCI) | |
| Improving Communication in Older Cancer Patients and Their Caregivers | NCT02107443 | Adult Solid Neo... Lymphoma | Geriatric Asses... Geriatric Asses... Geriatric Asses... | 70 Years - | University of Rochester | |
| Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT01375829 | Adult Solid Neo... | Ixabepilone Pharmacological... Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors | NCT01218620 | Adult Solid Neo... | Gamma-Secretase... Ketoconazole Rifampin Midazolam Hydro... Omeprazole Tolbutamide Dextromethorpha... Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors | NCT01971489 | Adult Solid Neo... Recurrent Non-S... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-Sm... | Buparlisib Cisplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological... Questionnaire A... | 18 Years - | Roswell Park Cancer Institute | |
| A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain | NCT01269918 | Adult Intracran... Adult Solid Tum... | Remifentanil Dexmedetomidine | 18 Years - 80 Years | The Cleveland Clinic | |
| Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme | NCT01122888 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Solid Neo... Recurrent Adult... | Cilengitide Clinical Observ... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 | NCT02775292 | Adult Solid Neo... Childhood Solid... Metastatic Neop... | Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Nivolumab NY-ESO-1 Reacti... NY-ESO-1(157-16... Positron Emissi... | 16 Years - | Jonsson Comprehensive Cancer Center | |
| Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 | NCT02775292 | Adult Solid Neo... Childhood Solid... Metastatic Neop... | Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Nivolumab NY-ESO-1 Reacti... NY-ESO-1(157-16... Positron Emissi... | 16 Years - | Jonsson Comprehensive Cancer Center | |
| Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | NCT01093092 | Adult Solid Neo... | Calcitriol Cisplatin Gemcitabine Hyd... Pharmacological... | 18 Years - | Roswell Park Cancer Institute | |
| Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies | NCT01061749 | Adult Solid Neo... | Cixutumumab Laboratory Biom... Pharmacological... Selumetinib | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
